Viridian Therapeutics, Inc. (VRDN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
221 Crescent Street
Waltham, MA 02453
United States of America (the)
Phone
617 272 4600
Sector
Healthcare
Industry
Biotechnology
Employees
143
First IPO Date
June 18, 2014
| Name | Title | Pay | Year Born |
| Stephen F. Mahoney | Chief Executive Officer, President & Director | 1.34M | 1971 |
| Seth Harmon | Chief Financial Officer | 785,651 | 1981 |
| Jennifer Tousignant | Chief Legal Officer & Corporate Secretary | 819,951 | 1973 |
| Radhika Tripuraneni | Chief Medical Officer | 840,686 | 1980 |
| Thomas W. Beetham | Chief Operating Officer | 972,976 | 1970 |
| Melissa Manno | Chief Human Resources Officer | 0 | N/A |
| Eric N. Olson | Co-Founder & Chairman of Scientific Advisory Board | 0 | N/A |
| Marvin H. Caruthers | Co-Founder & Scientific Advisory Board Member | 0 | 1940 |
| Michael R. Bristow | Co-Founder & Member of the Scientific Advisory Board | 0 | 1945 |
| Vahe Bedian | Co-Founder & Scientific Advisor | 0 | N/A |
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.